AskBio recently started a phase 2 trial of AB-1002, called GenePHIT, that will compare two doses of AB-1002 to placebo in around 150 patients with NYHA Class III heart failure, with a primary analysis …
Read Full Story at source (may require registration)
- How to Sell a Small Business: A Starter Guide for Business Owners - February 3, 2025
- European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024
- FTSE 100 Modestly Higher In Cautious Trade - November 27, 2024